Arcus Biosciences Inc
NYSE:RCUS
Intrinsic Value
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. [ Read More ]
The intrinsic value of one RCUS stock under the Base Case scenario is 14.3 USD. Compared to the current market price of 18.88 USD, Arcus Biosciences Inc is Overvalued by 24%.
Valuation Backtest
Arcus Biosciences Inc
Run backtest to discover the historical profit from buying and selling RCUS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Strong Prospects for HIF2-alpha Program
2023-Q4 Earnings Call
The company sees their HIF2-alpha inhibitor as a major opportunity, suggesting its potential for significance within the pharmaceutical landscape akin to Merck's blockbuster. They believe their molecule has a competitive advantage as they can pursue fivefold higher dosages, leading to greater efficacy without indications of increased toxicity. Furthermore, their PK/PD profile shows promise, and no dose-limiting toxicities (DLTs) have been observed. The company will continue to evaluate their pipeline, including the discontinued ARC-10 trial, and decide on the strategic direction based on data maturity and impact on ongoing studies.
Balance Sheet Decomposition
Arcus Biosciences Inc
Current Assets | 831m |
Cash & Short-Term Investments | 759m |
Receivables | 42m |
Other Current Assets | 30m |
Non-Current Assets | 264m |
Long-Term Investments | 107m |
PP&E | 143m |
Other Non-Current Assets | 14m |
Current Liabilities | 184m |
Accounts Payable | 17m |
Accrued Liabilities | 76m |
Other Current Liabilities | 91m |
Non-Current Liabilities | 449m |
Other Non-Current Liabilities | 449m |
Earnings Waterfall
Arcus Biosciences Inc
Revenue
|
117m
USD
|
Operating Expenses
|
-457m
USD
|
Operating Income
|
-340m
USD
|
Other Expenses
|
33m
USD
|
Net Income
|
-307m
USD
|
Free Cash Flow Analysis
Arcus Biosciences Inc
What is Free Cash Flow?
RCUS Profitability Score
Profitability Due Diligence
Arcus Biosciences Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Arcus Biosciences Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
RCUS Solvency Score
Solvency Due Diligence
Arcus Biosciences Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Arcus Biosciences Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RCUS Price Targets Summary
Arcus Biosciences Inc
According to Wall Street analysts, the average 1-year price target for RCUS is 39.98 USD with a low forecast of 24.24 USD and a high forecast of 73.5 USD.
Ownership
RCUS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RCUS Price
Arcus Biosciences Inc
Average Annual Return | 38.11% |
Standard Deviation of Annual Returns | 96.99% |
Max Drawdown | -72% |
Market Capitalization | 1.7B USD |
Shares Outstanding | 90 860 000 |
Percentage of Shares Shorted | 12.69% |
RCUS News
Last Important Events
Arcus Biosciences Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Arcus Biosciences Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 366 full-time employees. The company went IPO on 2018-03-15. The firm's six investigational products are in the clinical development, with its molecule, an anti-TIGIT antibody, which is in two phase III registrational studies. The firm's differentiated combination therapies are developing to treat multiple large tumor types, including lung, colorectal, prostate and pancreatic cancers. Its clinical development pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Zimberelimab and AB521. Domvanalimab is its Fc-silent anti-TIGIT monoclonal antibody. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors. Quemliclustat is an extremely potent and selective small-molecule CD73 inhibitor. Zimberelimab is its anti-PD-1 antibody.
Contact
IPO
Employees
Officers
The intrinsic value of one RCUS stock under the Base Case scenario is 14.3 USD.
Compared to the current market price of 18.88 USD, Arcus Biosciences Inc is Overvalued by 24%.